Harvard Bioscience, Inc.
HBIO
$0.76
$0.011.55%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -6.28% | -11.46% | -11.17% | -12.78% | -13.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.28% | -11.46% | -11.17% | -12.78% | -13.38% |
| Cost of Revenue | -6.90% | -9.74% | -1.54% | -8.74% | -13.45% |
| Gross Profit | -5.83% | -12.75% | -17.52% | -15.57% | -13.32% |
| SG&A Expenses | -16.76% | -20.58% | -14.42% | -10.82% | -8.49% |
| Depreciation & Amortization | -35.91% | -12.70% | -12.98% | -9.37% | -1.98% |
| Other Operating Expenses | -- | -- | -82.30% | -- | -- |
| Total Operating Expenses | -14.02% | -14.94% | -12.66% | -11.64% | -10.01% |
| Operating Income | 114.45% | 63.00% | 28.74% | -48.02% | -81.67% |
| Income Before Tax | 74.75% | 31.28% | -1,032.78% | 153.49% | -699.11% |
| Income Tax Expenses | -68.81% | 107.93% | -316.19% | -20.00% | -54.06% |
| Earnings from Continuing Operations | 74.36% | 22.04% | -972.43% | 100.99% | -287.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.36% | 22.04% | -972.43% | 100.99% | -287.57% |
| EBIT | 114.45% | 63.00% | 28.74% | -48.02% | -81.67% |
| EBITDA | 1,207.50% | 678.91% | 106.22% | -16.58% | -85.82% |
| EPS Basic | 74.93% | 23.48% | -955.08% | 100.94% | -279.66% |
| Normalized Basic EPS | 75.40% | 22.46% | 14.66% | 1,625.00% | -138.61% |
| EPS Diluted | 72.75% | 23.48% | -937.82% | 100.94% | -267.00% |
| Normalized Diluted EPS | 75.40% | 22.46% | 14.66% | 1,600.00% | -138.61% |
| Average Basic Shares Outstanding | 2.16% | 1.88% | 1.60% | 2.22% | 2.17% |
| Average Diluted Shares Outstanding | 2.16% | 1.88% | 1.60% | 4.08% | 2.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |